Send to

Choose Destination
Alzheimers Dement. 2008 Mar;4(2):80-8. doi: 10.1016/j.jalz.2008.02.004.

Partnership between academia and industry for drug discovery in Alzheimer's disease.

Author information

Harvard NeuroDiscovery Center, Harvard Medical School, Boston, MA, USA.

Erratum in

  • Alzheimers Dement. 2008 May;4(3):230-1.


Drug discovery has traditionally been almost exclusively the purview of pharmaceutical and biotechnology companies, whereas universities have focused on basic research. However, given the challenges involved in discovering and developing truly effective, symptomatic treatments and disease-modifying drugs for Alzheimer's disease, there is a need to reassess this simple division of labor. Whereas each sector is likely to retain a core interest and expertise at either end of the drug discovery spectrum, there is room for closer cooperation at the intersection of the for-profit and not-for-profit sectors. The Alzheimer's Association Research Roundtable convened a meeting of senior industry researchers and academic investigators to discuss this intersection and to assess the opportunity for closer partnership on Alzheimer's disease drug discovery and development.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center